

# SCIENTIFIC REPORTS



OPEN

## Altered protein phosphorylation as a resource for potential AD biomarkers

Ana Gabriela Henriques<sup>1,\*</sup>, Thorsten Müller<sup>2,\*</sup>, Joana Machado Oliveira<sup>1</sup>, Marta Cova<sup>1</sup>, Cristóvão B. da Cruz e Silva<sup>3</sup> & Odete A. B. da Cruz e Silva<sup>1</sup>

Received: 16 February 2016

Accepted: 04 July 2016

Published: 28 July 2016


The amyloidogenic peptide, A $\beta$ , provokes a series of events affecting distinct cellular pathways regulated by protein phosphorylation. A $\beta$  inhibits protein phosphatases in a dose-dependent manner, thus it is expected that the phosphorylation state of specific proteins would be altered in response to A $\beta$ . In fact several Alzheimer's disease related proteins, such as APP and TAU, exhibit pathology associated hyperphosphorylated states. A systems biology approach was adopted and the phosphoproteome, of primary cortical neuronal cells exposed to A $\beta$ , was evaluated. Phosphorylated proteins were recovered and those whose recovery increased or decreased, upon A $\beta$  exposure across experimental sets, were identified. Significant differences were evident for 141 proteins and investigation of their interactors revealed key protein clusters responsive to A $\beta$  treatment. Of these, 73 phosphorylated proteins increased and 68 decreased upon A $\beta$  addition. These phosphorylated proteins represent an important resource of potential AD phospho biomarkers that should be further pursued.

The A $\beta$  peptide, derived by proteolytic cleavage<sup>1,2</sup> of the Alzheimer's Amyloid Precursor Protein (APP), is associated with the onset of Alzheimer's disease (AD). A $\beta$ , typically around 40 amino acids long, is produced under basal conditions but in familial AD (Swedish mutation) the rate can increase by almost 10 fold<sup>3</sup>. Peptides range in length<sup>4,5</sup>; the longer species are more toxic. A $\beta$  can be deposited as senile plaques (SPs) in AD patients' brains and is generated via the endosomal/lysosomal degradation pathway, but its production can also be associated to the ER and Golgi/TGN<sup>6</sup>. However it is not solely a toxic peptide, as it appears to have important physiological functions. A $\beta$  is present in the cerebral spinal fluid of AD patients but also of non-demented individuals and in media from neuronal cell cultures<sup>7-9</sup>. Further, A $\beta$  appears to be involved in synaptic activity and protect against excessive glutamate release<sup>10,11</sup>, thus it is involved in excitability and neuronal survival. Other functions, include monitoring cholesterol transport<sup>12</sup> and it may even have a role as a transcription factor<sup>13</sup>.

Protein phosphorylation is a key mechanism and regulates many cellular processes. Consequently abnormal protein phosphorylation has been linked to numerous human diseases including AD. Both APP and TAU phosphorylation have been associated with this dementia<sup>14,15</sup>. TAU, in a hyperphosphorylated state, forms neurofibrillary tangles (NFTs) which can deposit in the brain<sup>16</sup>. In AD other brain proteins such as neurofilaments, MAP1B, dynein, CRMP-2,  $\beta$ -tubulin and  $\beta$ -catenin are also hyperphosphorylated. Consistently, in AD, kinase activities and/or expression can be increased (GSK3 $\beta$ , CDK5, ERK1/2, JNK, p38MAPK). Likewise protein phosphatase (PP) activities and/or expression can be decreased (PP1, PP2, and PTEN - phosphatase and tensin homolog)<sup>17</sup>. Taken together, it is evident that protein (de)phosphorylation mechanisms are dysregulated in AD.

A $\beta$  links many AD related anomalies. It can activate Src family protein kinases, activate phosphatidylinositol 3-kinase<sup>18</sup> and the cAMP response element-binding protein phosphorylation<sup>19</sup>. A $\beta$  mediated changes can result in phosphorylation of neuronal proteins, and contribute to the critical early AD pathogenic events, culminating in neuronal death and neurodegeneration<sup>20</sup>. Furthermore, A $\beta$  is directly involved in stimulating kinases<sup>21-23</sup> and inhibiting PP1 and PP2 activities, in a dose-dependent manner<sup>24</sup>. It is therefore not surprising that A $\beta$  prompts the production of NFTs via mediating the expression levels and/or activities of TAU protein kinases and phosphatases<sup>21,25</sup>.

<sup>1</sup>Neuroscience and Signalling Laboratory, Department of Medical Sciences and Institute of Biomedicine - iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal. <sup>2</sup>Cell Signaling in Neurodegeneration (CSIN), Medical Proteome-Center, Ruhr-University Bochum, 44801 Bochum, Germany. <sup>3</sup>Laboratório de Instrumentação e Física Experimental de Partículas - LIP, Av. Elias Garcia 14 - 1º, 1000-149 Lisboa, Portugal. \*These authors contributed equally to this work. Correspondence and requests for materials should be addressed to A.G.H. (email: aghenriques@ua.pt)



**Figure 1. Workflow.** The workflow describes sample processing and analysis. Primary rat neuronal cortical cultures were treated with A $\beta$ , the lysates were collected and the phosphorylated proteins enriched in the phospho column. The eluted peptides were analyzed by mass spectrometry and the resulting data handled by the SysBioTK.

Clearly A $\beta$  affects distinct cellular pathways many of which are regulated by reversible protein phosphorylation. In the work herein described primary neuronal culture lysates were collected upon A $\beta$  exposure, enriched for phosphorylated proteins and the latter identified by mass spectrometry analysis. The approach revealed a series of phosphorylated proteins, whose levels were significantly altered upon A $\beta$  exposure, across experimental sets. The proteins identified are strong biomarker candidates, and the networks presented reveal novel protein relationships and signalling cascades, relevant to unraveling the molecular basis of AD.

## Results

**Enrichment of the phosphoproteomes.** Primary neuronal cultures were exposed to A $\beta$  and phosphorylated proteins enriched using the phospho column, were subjected to mass spectrometry analysis (Fig. 1). For all peptides obtained an accession IPI number was attributed. Although it was not the primary aim to identify specific phosphorylation sites, these were nonetheless readily detected. As examples, for the TAU protein (*Mapt* gene), three phosphorylated peptides (phosphopeptides) were identified (Supplementary Fig. S1) and one phosphorylated peptide was identified for GAPDH accession number IPI (Supplementary Fig. S2).


The data obtained from the mass spectrometry was subsequently analyzed using an informatics library (SysBioTK – Systems Biology Toolkit), specifically developed for this purpose (<https://bitbucket.org/CrisXed/sysbiotk>). An essential capacity of this platform is to translate accession number IPI to UniProt. The resulting accession numbers and corresponding gene lists were either handled by the SysBioTK (da Cruz e Silva, 2016 submitted), or submitted to other open access analysis tools.

Six experiments were carried out, to evaluate the phosphorylated proteins under basal conditions and upon A $\beta$  exposure. As an initial step, all experimental datasets were analyzed for outliers by the modified Thompson tau,  $\tau$ , test, (Fig. 1) and one of the experiments from the control condition was removed (Supplementary Table S1).

**Gene Ontology analysis.** Under the experimental conditions implemented (Supplementary Table S1), 986 phosphoproteins were recovered following A $\beta$  exposure (GpA $\beta$ –groupA $\beta$ ) and 870 phosphoproteins under control conditions (GpC–groupControl).

The GpC and GpA $\beta$  phosphatomes were analyzed with respect to Gene Ontology (GO) (Fig. 2). The distribution of the phosphorylated proteins across Molecular Functions and Biological Processes, for both GpA $\beta$  and GpC is similar. Top Biological Processes with the greater number of phosphorylated proteins are ‘anatomical structure development’, ‘transport’, ‘cellular nitrogen compound metabolic’, ‘cell differentiation’ and ‘signal transduction’. Top Molecular Functions identified are ‘ion binding’, ‘RNA binding’ and ‘enzyme binding’. There are no dramatic shifts or the appearance of novel Biological Processes or Molecular Functions upon A $\beta$  treatment, but in global terms the number of phosphorylated proteins increased marginally across all the GO categories. This is consistent with A $\beta$  promoting protein phosphorylation and inhibiting protein dephosphorylation.

**Deciphering the A $\beta$  induced phosphointeractome.** The GpA $\beta$  gene list was submitted to IntAct, the interacting proteins identified and the phosphointeractome analyzed using Cytoscape 3.3.0 (Fig. 3A). Data output from IntAct identifies the gene (represented in italics in the text), eventhough the experimental procedures yielding the phosphoproteins and the mass spectrometry data are identifying proteins (normal font in the text). In the resulting A $\beta$  induced phosphointeractome (Fig. 3A) the light grey nodes denote the genes corresponding to the recovered phosphorylated proteins and the dark grey nodes their interactors; identified in IntAct. Of note,



**Figure 2. Gene Ontology of the phosphatomes.** Genes encoding the eluted phosphorylated proteins under basal (GpC, black bars) conditions and upon A $\beta$  addition (GpA $\beta$ , grey bars) were analyzed with respect to their Gene Ontology (GO) using the SysBioTK for Biological Process and Molecular Function. Abbreviations of GOs not in full: GO:0048856 anatomical structure development; GO:0034641 cellular nitrogen compound metabolic process; GO:0030154 cell differentiation; GO:0022607 cellular component assembly; GO:0007165 signal transduction; GO:0006950 response to stress; GO:0009058 biosynthetic process; GO:0065003 macromolecular complex assembly; GO:0006464 cellular protein modification process; GO:0007010 cytoskeleton organization; GO:0009056 catabolic process; GO:0016192 vesicle-mediated transport; GO:0044281 small molecule metabolic process; GO:0006461 protein complex assembly; GO:0019899 enzyme binding; GO:0005198 structural molecule activity; GO:0030234 enzyme regulator activity; GO:0008092 cytoskeletal protein binding; GO:0016491 oxidoreductase activity; GO:0022857 transmembrane transporter activity.

phosphorylated TAU (*Mapt*) and phosphorylated APP were recovered (Fig. 3A). In the phosphointeractome two major clusters are readily evident and have as central nodes *Slc2a4* and *Mapk3*. *App* connects to *Slc2a4* via the *Tnf* node. The former is involved in glucose transport and the latter encodes a serine/threonine kinase.

**A $\beta$  modulates a phosphatase sub network.** Given the A $\beta$  phosphatase inhibitory role and the importance of phosphatases in AD<sup>15,24,26</sup> pathology, a sub network with respect to protein phosphatases, TAU and APP was elaborated. From the interactome in Fig. 3A, the nodes for phosphatases, *App*, *Mapt* and their direct interactors were extracted, and the sub-network was plotted using cytoscape (Fig. 3B). It is noteworthy that two central nodes, *Slc2a4* and *Mapk3* (dark grey nodes, Fig. 3B) are sustained in both networks (Fig. 3A,B) and bind directly to proteins whose levels of phosphorylation alter significantly following A $\beta$  exposure. In particular, the recovery of phosphorylated GAPDH and ALDOA proteins, decreased upon A $\beta$  addition.


In contrast several phosphorylated proteins appeared 'de novo' upon A $\beta$  addition. Two experimentally recovered, protein phosphatases, PPM1E and PTPN11 (Fig. 3B), were found in the GpA $\beta$  but not in the GpC (bright red nodes). PTPN11 phosphorylation increased significantly upon A $\beta$  addition and in turn it interacts with another five phosphorylated proteins recovered in the experimental procedures employed.

Furthermore serine/threonine protein phosphatases, and their regulators, appear to be hub nodes in the network depicted in Fig. 3B. *Ppp1ca*, *Ppp1cb* and *Ppp1cc* code for serine/threonine-protein phosphatase 1 (PP1) catalytic subunits  $\alpha$ ,  $\beta$  and  $\gamma$ , respectively. Significantly, PP1 $\alpha$  (*Ppp1ca*) is recovered only in GpA $\beta$  but not in GpC. That is, phosphorylated peptides for PP1 $\alpha$  were identified only when A $\beta$  was added to the primary neuronal cultures (Fig. 3B and Table 1). Peptides for this protein were absent in the mass spectrometry analysis of the GpC, suggesting that phosphorylated PP1 $\alpha$  is preferentially found upon A $\beta$  exposure. Activity of these phosphatases is regulated by regulatory subunits of which three were recovered; PPP1R9A, PPP1R9B and PPP1R12A. As mentioned, the latter is a PP1 regulatory subunit recovered in GpA $\beta$  but not in GpC.

*Ppp3ca* and *Ppp3cb* are serine/threonine-protein phosphatase 3 catalytic subunits  $\alpha$  and  $\beta$  (PP2B). PP2B is a phosphatase abundantly expressed in the CNS and implicated in AD pathology. It is interesting to note that both of these catalytic subunits were recovered in GpA $\beta$  and in GpC (Fig. 3).

Of the above mentioned serine/threonine protein phosphatases, and their regulators, only protein phosphatase PPP1CA and the phosphatase regulatory subunit PPP1R12A increased significantly, precisely by being recovered in their phosphorylated species in response to A $\beta$  exposure. The latter are direct interactors of *Slc2a4*.

**Analysis of A $\beta$  induced phosphointeractome.** Using the SysBioTK, phosphoproteins recovered in GpA $\beta$  were compared with those recovered in the GpC. One hundred forty one phosphoproteins that significantly change across experimental sets were identified. Phosphorylated proteins whose recovery rate was significantly 'higher' (increased) or 'lower' (decreased) were identified, herein designated as 'higher' or 'lower' phosphoproteins. To summarize 73 phosphoproteins were 'higher' and 68 'lower', upon A $\beta$  addition (Table 1). Within the 'lower' phosphoproteins, 19 were absent in the GpA $\beta$  (A $\beta$  'lost'), and this was significant when compared to the



**Figure 3. A $\beta$  phosphointeractome.** The A $\beta$  responsive phosphointeractome is depicted in (A). To obtain the phosphointeractome the phosphorylated and significantly different proteins, recovered experimentally upon A $\beta$  addition, were submitted to IntAct and the interactome produced using Cytoscape 3.3.0. Cluster analysis was carried out using the Cytoscape plugin clusterMaker (GLay). The light grey nodes correspond to the phosphorylated proteins recovered in the experimental procedures and the dark grey nodes their interactors, as identified in IntAct. *Mapt* (encodes the TAU protein) and *App* are represented as blue nodes and the corresponding edges are colour coded also in blue. Two major clusters are identified; with the central nodes *Slc2a4* and *Mapk3* with the circumference and edges in blue. *App* connects to the *Slc2a4* cluster via the *Tnf* node (circumference in purple). A phosphatase sub network is represented in (B). (B) was extracted from (A) by selecting phosphatases, *App*, *Mapt* and their direct interactors. Bright red nodes were detected only upon A $\beta$  addition (not under basal conditions) and light green nodes represent proteins whose phosphorylation levels decreased significantly upon A $\beta$  addition.

GpC. In contrast 50 phosphoproteins were recovered only in conditions where A $\beta$  was added (A $\beta$  'exclusive'), again these were significantly different across experimental sets, applying the Welch's t-test (Fig. 1).

The GO of significantly different 'higher' and 'lower' phosphoproteins were analyzed for Biological Process (Fig. 4). The top groups, for Biological Processes, are those where the 'higher' phosphoproteins are greater than the 'lower' phosphoproteins, the net effect is an increase in phosphorylated proteins. Top functions are consistent with functions described for APP and furthermore, have been associated with AD, for example signal transduction and vesicle-mediated transport.

The middle group of Biological Processes, are those where the 'lower' phosphoproteins are greater than the 'higher' phosphoproteins, the net effect is a decrease in phosphorylated proteins (Fig. 4). Top functions within this group, include small molecule metabolic processes, cytoskeletal organization and transmembrane transport, these processes have also been associated with AD.

In the bottom group (Fig. 4), the number of 'higher' and 'lower' phosphoproteins is similar. However although the number of proteins is sustained, the proteins are different. To better understand the underlying molecular processes, proteins were analyzed as described below.

**Interactome of significantly different phosphoproteins upon A $\beta$  exposure.** From the A $\beta$  phosphointeractome (Fig. 3A), a simplified network was developed using subsets of nodes (Fig. 5). The following classes of nodes and their direct interactors were selected; genes corresponding to significantly 'higher' and 'lower' phosphoproteins identified across experimental sets (listed in Table 1), as well as those from the GpA $\beta$  with the GO term 'protein phosphatase'. The nodes *App* and *Mapt* were also included. The interactions were plotted as a network using Cytoscape 3.3.0 (Fig. 5 and Supplementary Table S2). Bright green nodes correspond to A $\beta$

'Lower' Phosphoproteins			'Higher' Phosphoproteins		
<i>Actn1</i>	Hspa12a	Rbm14	<b>Abi2</b>	<b>Gtpbp1</b>	Psip1
Aldh18a1	Hspd1	<b>Rhot1</b>	Ap2s1	Hexa	Psmb6
Aldoa	Krt14	Rpn1	<b>Ap3b2</b>	<b>Hk1</b>	<b>Psmd13</b>
Alg2	Krt75	Ruvbl2	Atp6v1h	<b>Idh3B</b>	<b>Ptpn11</b>
Ap2a2	Lancl2	Sfxn1	<b>Bcat1</b>	<b>Ikbkap</b>	<b>Rab11a</b>
<i>Apc</i>	Lasp1	Slc25a12	<b>Bid</b>	<b>Ilf3</b>	<b>Rab35</b>
<i>Atp5f1</i>	Llgl1	<b>Slc39a10</b>	<b>Camk2d</b>	<b>Impdh1</b>	<b>Rab6a</b>
<i>Atp5j2</i>	<b>Ly75</b>	<b>Slc3a2</b>	Cdc5l	Itsn1	Ran
Atp6v1b2	<b>Magi1</b>	Soga3	<b>Cdh6</b>	<b>Lrrc8a</b>	Rtcb
<i>Atp6v1e1</i>	Magi2	<u>Sptbn1</u>	Clip2	<b>Lrrfip1</b>	<b>Sf3a1</b>
<i>Brk1</i>	Map1s	Stmn2	<b>Cndp2</b>	<b>Lrrfip2</b>	Slc25a22
Cand1	Map4k4	<u>Strbp</u>	Csde1	<b>Madd</b>	<b>Smc3</b>
<i>Ccdc92</i>	Marcks	<b>Tf</b>	<b>Ctps1</b>	Nap1l1	<b>Snrnp70</b>
Cdc42bpb	<b>Mat2a</b>	Tmx1	<b>Ddx3y</b>	<u>Ncam1</u>	<b>Snw1</b>
<i>Cfl2</i>	Mdh2	Tpm1	<b>Dhx30</b>	<b>Nucb2</b>	<u>Sptbn1</u>
<i>Chmp2b</i>	<u>Ncam1</u>	Uba1	<b>Dip2c</b>	<b>Numbl</b>	<u>Strbp</u>
Cyc1	Ndufs1	Usp5	<b>Dynlrb1</b>	<b>Pabpc1</b>	<b>Tbc1d19</b>
Dbnl	Pfkm	<u>Wdr47</u>	Eci1	<b>Pc</b>	<b>Tceb1</b>
Dctn1	Prkcsch		Eef1a1	<b>Pdcd5</b>	<b>Timm13</b>
Erp29	Psmb5		Eef2	Picalm	<b>Trappc2</b>
Farp1	Psmd11		<b>Ehd1</b>	<b>Pip5k1c</b>	<b>Ube4b</b>
G3bp2	Psmc1		<b>Ehd3</b>	<b>Plcg1</b>	Wdfy1
Gapdh	<b>Rab10</b>		<b>Enah</b>	<b>Ppm1e</b>	<u>Wdr47</u>
Gls	<b>Rasl2-9</b>		Epn2	<b>Ppp1ca</b>	
Gpsm1	<b>Rbbp7</b>		<b>Fmr1</b>	<b>Ppp1r12a</b>	

**Table 1. Significantly different recovery rates of phosphoproteins upon A $\beta$  addition.** Upon A $\beta$  addition the number of phosphorylated proteins recovered decreased significantly ('lower' Phosphoproteins) while others increased ('higher' Phosphoproteins). The genes encoding these significantly different proteins were identified using the SysBioTK (Welch's t-test). Genes underlined correspond to the same protein recovered under both conditions, although different identifiers were involved (see Supplementary Table S2). Genes in bold and italics correspond to phosphoproteins present under control conditions but absent (A $\beta$  'lost') upon A $\beta$  addition and genes in bold correspond to phosphoproteins detected only upon addition of A $\beta$  (A $\beta$  'exclusive').

'lost' phosphoproteins and bright red nodes to A $\beta$  'exclusive' phosphoproteins comparative to Control conditions. Fifteen clusters were identified with the Cytoscape plugin clusterMaker (GLay).


**Unaltered phosphoproteins as central nodes.** Clusters 1 (*Ppp1cc*), 2 (*Ppp3ca*) and 12 (*Ppp3cb*) include phosphatases (Fig. 5 and Supplementary Table S2) that have already been discussed and whose phosphorylation levels do not alter significantly upon A $\beta$  addition. An exception is the *Ppp3ca* cluster (cluster 2) where CAMK2D exhibits 'higher' phosphorylation. Cluster 12 includes nodes *Ppp3cb* and *Slc8a3*, evoking putative functional links to long-term memory potentiation, given the biological function of these proteins. These functions are significantly compromised in AD, and it is relevant that the A $\beta$  induced phospho network includes these nodes (Fig. 5).

Clusters 9 (*Synj1*) and 8 (*Camk2a*) include *Mapt* and *App* respectively (Fig. 5 and Supplementary Table S2). Other nodes in cluster 9, include *Dnm1*, *Itsn1*, *Picalm* and *Dbnl*. ITSN1 and PICALM, revealed 'higher' phosphorylation levels upon A $\beta$  addition, in contrast DBNL has 'lower' levels.

The central node in cluster 8 is *Camk2a*, crucial for plasticity at glutamatergic synapses. This calcium calmodulin-dependent protein kinase is composed of four different chains: alpha, beta, gamma, and delta. CAMK2A interacts directly with ACTN1, but following A $\beta$  addition the phosphorylated form of the latter is no longer recovered. ACTN1 is involved in the regulation of the actin cytoskeleton. *Atp5f1* is another A $\beta$  'lost' phosphoprotein in this cluster, in contrast proteins encoded by *Slc25a22* and *Psmd13* show 'higher' phosphorylated levels in response to A $\beta$ , the latter is A $\beta$  'exclusive'.

Cluster 5 (*Dlg2/Dlg3/Dlg4*) includes DLG family members (Fig. 5 and Supplementary Table S2), which are essential for maintaining synaptic architecture and plasticity. These proteins although well represented as phosphoproteins in the primary neuronal cell cultures, did not alter significantly upon A $\beta$  exposure (dark grey nodes).

**'Lower' and 'Higher' phosphoproteins as central nodes.** The *Dlg* cluster 5 has another central node, *Magi2* (Fig. 5 and Supplementary Table S2). MAGI2 is a 'lower' phosphoprotein also involved in development and maintenance of the synapse. Even though cluster 5 does not have a substantial number of nodes that are significantly altered following A $\beta$  exposure, the phosphorylated protein APC is A $\beta$  'lost'. *Cdc42bpb* is another central node (cluster 13) exhibiting 'lower' phosphorylation across experimental sets.




**Figure 4. Gene Ontology of significantly different phosphorylated proteins.** The two sets of proteins (GpC and GpA $\beta$ ) were grouped with respect to their Gene Ontology using the SysBioTK for Biological Process. Red bars represent the phosphorylated proteins whose recovery increased upon A $\beta$  addition ('higher' phosphoproteins). Green bars represent the phosphorylated proteins whose recovery decreased upon A $\beta$  addition ('lower' phosphoproteins). Abbreviations of GOs not in full: GO:0034641 cellular nitrogen compound metabolic process; GO:0048856 anatomical structure development; GO:0007165 signal transduction; GO:0009058 biosynthetic process; GO:0016192 vesicle-mediated transport; GO:0006464 vesicle-mediated transport; GO:0006464 cellular protein modification process; GO:0009056 catabolic process; GO:0030154 cell differentiation; GO:0022607 cellular component assembly; GO:0044281 small molecule metabolic process; GO:0007010 cytoskeleton organization; GO:0006461 protein complex assembly; GO:0055085 transmembrane transport; GO:0005975 carbohydrate metabolic process; GO:0006950 response to stress; GO:0065003 macromolecular complex assembly.

Clusters with central nodes that represent 'higher' phosphoproteins, are in general terms smaller (Fig. 5 and Supplementary Table S2); these include clusters 14 (*Enah*), 15 (*Ehd1*), 3 (*Plcg1*), 7 (*Rab11a*) and 10 (*Rab6a*). *Plcg1* is involved in regulating intracellular signalling cascades and in this cluster besides *Pabpc1*, *Ncam 1* also exhibited 'higher' recovery of the phosphorylated proteins. Two clusters have as central nodes RAB11a (cluster 7) and RAB6a (cluster 10), these proteins are small GTPases involved in intracellular membrane trafficking. *Rab11a* is A $\beta$  'exclusive' and *Rab6a* represents likewise an A $\beta$  'exclusive' 'higher' phosphoprotein. Another 'higher' phosphoprotein identified in the latter cluster is PTPN11, already discussed. In contrast RAB10 (cluster 10) is A $\beta$  'lost' and phosphorylated DCTN1 is significantly 'lower'.

**Bioinformatically identified central nodes.** Three clusters 11, 4 and 6, have central nodes, which were not experimentally identified but became evident following the bioinformatics analysis. Cluster 11 (*Nr3c1*) is a small cluster and includes PPP6C, LASP1 a 'lower' phosphoprotein and TCEB1 that is A $\beta$  'exclusive'. Clusters 4 (*Slc2a4*) and 6 (*MapK3*), with central nodes already discussed, contain the greatest number of significantly different phosphoproteins. Taken together they include three A $\beta$  'lost' phosphoproteins and eleven A $\beta$  'exclusive'.

**Significantly different phosphoprotein network.** Many of the 'higher' and 'lower' phosphoproteins have been reported to interact, thus the identifiers in Table 1 were submitted to STRING and further interactions identified (Fig. 6). Nine clusters are particularly evident, with the central nodes *Actn1*, *Atp6v1e1*, *Gapdh*, *Hspd1*, *Rab11a/Numbl*, *Ran*, *Ppp1r12a*, *Eef2/Sfe1* and *Psmb6*. The first four clusters include predominantly 'lower' phosphoproteins and the last five, predominantly 'higher' phosphoproteins. Clusters were organized by degree such that the central nodes have the greatest number of edges and thus are the most likely key genes with respect to A $\beta$  induced responses. Hence the proteins they encode represent strong AD biomarker candidates, given that the recovery of the phosphorylated protein across experimental sets was significantly decreased or increased upon A $\beta$  addition. In some cases the recovery of the phosphoprotein was completely 'lost' or 'exclusive' following conditions of A $\beta$  addition (bright green and bright red nodes respectively, Fig. 6).

Many of the above mentioned central nodes have already been discussed, but close analysis of Fig. 6 reveals key cellular processes following A $\beta$  exposure. For example A $\beta$  induced reduced phosphorylation levels of; the



**Figure 5. A $\beta$  induced phospho network.** Figure 5 represents a subset from Fig. 3, retaining the nodes of significantly different phosphoproteins, as well as those with the term ‘protein phosphatase’ in their GO (black contour). Directly interacting nodes of the latter were maintained. The interacting proteins, that were identified in the experimental set up are coloured light grey; other interacting proteins are dark grey. Dark yellow nodes represent proteins that both increased and decreased upon A $\beta$  addition (see Supplementary Table S3). ‘Higher’ phosphoproteins are light red and phosphoproteins recovered only in conditions where A $\beta$  was added (A $\beta$  ‘exclusive’) are bright red. ‘Lower’ phosphoproteins are light green and phosphoproteins not recovered upon A $\beta$  addition (A $\beta$  ‘lost’) are bright green. The network was produced using Cytoscape 3.3.0 and cluster analysis was carried out using the Cytoscape plugin clusterMaker (GLay).

*Actn1* cluster which implies targeting cytoskeletal organization; the *Atp6v1e1* cluster impacting lysosomal, iron transport and ubiquitination processes; and the *Hspd1* cluster which is associated with the heat shock response.

Another cluster includes *Gapdh*, which plays a role in glycolysis and nuclear functions. This cluster has three phosphorylated proteins which are significantly ‘higher’ and five which are significantly ‘lower’ (Fig. 6), among them *Aldoa*; a glycolytic enzyme.

As previously mentioned A $\beta$  causes ‘higher’ *Rab6a* and *Rab11a* phosphorylation, but *Rab10* is A $\beta$  ‘lost’. Another phosphoprotein significantly decreased is AP2A2, a component of the adaptor protein complex 2 (AP2) involved in endocytosis related processes.


The *Ppp1r12a* cluster is particularly interesting from a biomarker standpoint as it includes 5 ‘higher’ A $\beta$  ‘exclusive’ phosphoproteins. This is also the case for the *eEf2* cluster. The latter is a member of the GTP-binding translation elongation factor family and an essential factor for protein synthesis.

## Discussion

Identification of significantly ‘higher’ and ‘lower’ phosphoproteins in response to A $\beta$  exposure, proved to be an important approach to providing key biomarker candidates. Analysis of the proteins, identified across experimental sets, with respect to Biological Process identified crucial processes that were corroborated, when the functions of the phosphorylated proteins themselves were investigated. Among the most recurring processes are signal transduction, endocytosis, cytoskeletal organization and intracellular transport. Alterations in these cellular events have in turn, all been associated with AD.

The phosphorylation levels of many proteins involved in membrane trafficking changed, as is the case of *ITSN1* whose phosphorylation levels increases in response to A $\beta$ . *ITSN1* has been implicated in Down’s syndrome and AD, possibly via c-JUN N terminal kinase activation<sup>27</sup>. It is a cytoplasmic membrane-associated protein involved in endocytic membrane traffic and appears to regulate the formation of clathrin-coated vesicles and to be involved in synaptic vesicle recycling. Furthermore, *ITSN1* was shown to interact with AP2<sup>28</sup>. Interestingly, AP2A2, a component of the AP2 adaptor complex, is a phosphoprotein significantly decreased upon A $\beta$  exposure. This complex is also involved in clathrin-dependent endocytosis and serves as a cargo receptor, selectively sorting the membrane proteins involved in receptor-mediated endocytosis. The *AP2A2* gene has been associated with AD<sup>29</sup>. Furthermore it is noteworthy that the complex AP2/*PICALM*, interacts with APP directing it to degradation and autophagy<sup>30</sup>. Given the important roles of endocytosis and A $\beta$  production in AD, genes impacting this process are extremely relevant.

RBAs comprise a subfamily of small GTPases also involved in the regulation of several steps during membrane trafficking, including vesicle formation, movement along the cytoskeleton network and fusion at the target



**Figure 6. A $\beta$  induced significantly different phospho network.** Protein interactions between phosphorylated proteins, whose recovery significantly increased ('higher') or decreased ('lower') following A $\beta$  addition, were mapped using STRING. 'Higher' phosphoproteins are light red and phosphoproteins recovered only in conditions where A $\beta$  was added (A $\beta$  'exclusive') are bright red. 'Lower' phosphoproteins are light green and phosphoproteins not recovered upon A $\beta$  addition (A $\beta$  'lost') are bright green. Dark yellow nodes represent the same protein, but distinct identifiers that increased and decreased in response to A $\beta$  addition (Supplementary Table S3). The network was produced using Cytoscape 3.3.0.

membrane. *Rab10* codes for an A $\beta$  'lost' phosphoprotein while *Rab11a*, cluster 7 in Fig. 5, is A $\beta$  'exclusive' and is significantly associated with late-onset AD<sup>31</sup>. *Rab6a* is likewise an A $\beta$  'exclusive' 'higher' phosphoprotein. RAB6 was shown to regulate intracellular APP processing and trafficking. Furthermore, upregulation of RAB6A in AD is linked to ER stress<sup>32</sup>. A $\beta$  can affect the phosphorylation states of many proteins involved in diverse cellular processes and induces stress. As an example, another central cluster includes *Gapdh* and *Aldoa*. GAPDH interacts with APP, and there is significant inhibition of the former in AD<sup>33</sup>. Further, oxidative modification appears to be a relevant neurotoxic pathway in AD cases correlated with GADPH. Alterations of ALDOA have also been associated with AD<sup>34</sup>.

Since APP processing and A $\beta$  production involve intracellular transport and vesicle-mediated transport<sup>35,36</sup>, one can hypothesize that A $\beta$  may be involved in regulating its own production, via modulating phosphorylation of proteins involved in the above mentioned cellular processes. The peptide was reported to alter APP nuclear signalling<sup>37</sup> and to impair APP secretion/vesicular anterograde transport and exocytosis, through a mechanism mediated by altered cytoskeleton dynamics of both microtubule and actin networks<sup>25,38</sup>.

Indeed, the actin cytoskeleton is also relevant for synaptic remodeling and AD pathogenesis<sup>25</sup>. Two cytoskeletal related phosphoproteins whose recovery rate decreased were identified. ACTN1 is a bundling protein and an F-actin cross-linking protein thought to anchor actin to a variety of intracellular structures. It is involved in the regulation of the actin cytoskeleton and is an A $\beta$  "exclusive" phosphoprotein. Reports have associated ACTN1 to AD<sup>39</sup>. *Cdc42bpb* is a central node (cluster 13) exhibiting 'lower' phosphorylation. It regulates actin cytoskeletal organization and is a downstream effector of CDC42, whose activity is increased upon A $\beta$  treatment<sup>40</sup>.

A $\beta$  affected the phosphorylation level of proteins directly involved in synaptic signalling. In particular, MAGI2 is a 'lower' phosphoprotein. It is a scaffold molecule at synaptic junctions and assembles neurotransmitter receptors and cell adhesion proteins. It appears to be essential for development and maintenance of the synapse, binding to other scaffold proteins supporting cell junctions<sup>41</sup>. MAGI2 and AD have not being extensively explored but genome-wide association studies placed this gene as a candidate locus in the etiology of sporadic AD.

Further, several members of the DLG family were also found, even though their phosphorylation did not change significantly in response to A $\beta$ . These proteins can be recruited to the post-synaptic density, where they are essential for maintaining synaptic architecture and plasticity. Both *DLG3* (encodes SAP-102) and *DLG4* (encodes PSD-95) have been associated with AD; their protein levels are reduced in AD brains<sup>42</sup>. Further, given



that *DLG3* and *DLG4* encode post-synaptic scaffold proteins, which regulate NMDA receptor synaptic activity and expression, this presents a possible mechanism for aberrant expression in AD. NMDA receptor-evoked excitotoxicity contributes to glutamatergic synapses mediating cognitive decline in AD<sup>42</sup>. *SYNJ1* is another protein whose phosphorylation levels did not change but its expression is likely to affect synaptic transmission and membrane trafficking. These are also hallmarks of the disease and *SYNJ1* was reported to increase in AD<sup>43</sup>.

Although not found under our experimental conditions, two central genes linking many altered phosphoproteins were identified by the IntAct searches; the *Slc2a4* and *MapK3* nodes. *Slc2a4* encodes a protein that functions as an insulin-regulated facilitative glucose transporter. Altered metabolism of brain glucose has been suggested in diabetes and AD<sup>44</sup>. Of note, decreased *SLC2A4* expression has been observed in adipose tissue from type 2 diabetic patients and diabetes is increasingly associated with AD. *MapK3* encodes a serine/threonine kinase; an essential component of the Map kinase signal transduction pathway. The MAPK/ERK cascade regulates many biological functions, such as cell adhesion, survival, growth and differentiation, regulation of transcription and translation, and cytoskeletal rearrangements. Moreover, this cascade regulates endosomal dynamics, lysosome processing and endosome cycling; these processes, have been associated with APP, TAU and AD. Increased activities and anomalies on MAPK signalling have been closely associated to disease pathology<sup>45</sup>.

The A $\beta$  impact on both kinases and phosphatases is well described. In this work a network of phosphatases whose phosphorylation increases in response to A $\beta$  was recovered. *Ptpn11* (protein tyrosine phosphatase, non-receptor type 11) is a “higher” phosphoprotein that interacts with many genes/proteins likewise altered. *Ptpn11* encodes a signalling molecule involved in activation of the RAS/MAPK pathway and STAT signalling pathways. *PTPN11* has been tagged as a hub gene in AD<sup>46</sup>. One can therefore deduce that phosphorylated *PTPN11* should be investigated as a potential AD biomarker. Of note, *Plcg1*, an A $\beta$  “exclusive” protein, can become activated in response to ligand-mediated activation of receptor-type tyrosine kinases and is involved in regulating intracellular signalling cascades. Further, *PLCG1* has been tagged as a hub gene in AD<sup>46</sup>.

Noticeably, *PP1 $\alpha$*  (*Ppp1ca*) is another phosphatase recovered only in GpA $\beta$ . *PP1* is an abundant neuronal phosphatase enriched in dendritic spines<sup>47,48</sup> with a key role in synaptic signalling; and it can be inhibited by A $\beta$ . *PP1* is required for long-term depression, is involved in memory and learning and has been implicated in TAU dephosphorylation, playing a key role in AD pathogenesis. Interestingly, the activity of phosphatases can be regulated by different regulatory subunits. *PPP1R12A* is a *PP1* regulatory subunit recovered in GpA $\beta$  but not in GpC.

*Ppm1e* encodes a member of the PP2C family of the serine/threonine-protein phosphatases that also exhibits increased phosphorylation. It is brain-specific, involved in synaptic plasticity and dendritic spine morphogenesis and negatively regulates the Ca<sup>2+</sup>/calmodulin dependent kinases (CaMK) IV and II and the p21-activated kinase (PAK) 1; kinases important in actin cytoskeletal regulation. This phosphoprotein may likewise represent an interesting target in AD pathology.

In conclusion, due to the dynamic nature of protein phosphorylation systems, where the phosphorylation of a given protein can evoke the phosphorylation of further proteins, it is not surprising that a given cluster can have both ‘higher’ and ‘lower’ phosphoproteins. This work clearly showed that A $\beta$  altered the phosphorylation levels of many proteins and this is consistent with the pathophysiological characteristics attributed to A $\beta$ , placing it at the center of AD. From the dataset here presented it was possible to identify 141 putative biomarkers, whose phosphorylated proteins significantly increased (73) or decreased (68) upon A $\beta$  addition across experimental sets. Furthermore 19 phosphoproteins were ‘lost’ upon A $\beta$  exposure and 50 were ‘exclusive’ to A $\beta$  addition. These proteins and their levels of phosphorylation provide a resource as potential phospho biomarker candidates for AD diagnosis and should be pursued in this respect in future studies.

## Online Methods

**Neuronal primary cultures.** Primary cortical neuronal cultures were prepared from Wistar Hannover rat embryo at 18<sup>th</sup> day of gestation as previously described<sup>37</sup>. Briefly, cerebral cortex was dissected and dissociated with trypsin (0,23 mg/mL) and desoxyribonuclease I (0,15 mg/mL) in Hanks balanced solution (HBSS). Cells were then plated onto poly-D-lysine coated dishes at 6 × 10<sup>6</sup> cells/100 mm density in Neurobasal medium (Gibco) supplemented with a serum-free medium combination of B27 (NB-B27), glutamine (0,5 mM) and gentamicin (60 µg/mL). Cells were maintained in an atmosphere of 5% CO<sub>2</sub> at 37 °C and experiments were carried out on the 10<sup>th</sup> day of primary neuronal cultures *in vitro*.

All experimental procedures followed the European legislation for animal experimentation (2010/63/EU) and no specific ethics approval under EU guidelines was required. This is within the European law (Council Directive 86/609/EEC) and during the procedure all steps were taken to ameliorate animal suffering. Procedures were approved and supervised by the Institutional Animal Care and Use Committee: Comissão Responsável pela Experimentação e Bem-Estar Animal (CREBEA).

**A $\beta$  treatment and phosphorylation mimicking conditions.** A $\beta$ 1-42 peptide (American peptide) was aggregated in PBS for 48 h at 37 °C (100 µM aggregated stock) as previously described<sup>49</sup>. After aggregation, A $\beta$  was added to primary neuronal cultures (Fig. 1), as a 10 µM solution in NB-B27 medium, for 3 h. Cell lysates were collected and the samples were processed for phosphoprotein enrichment as described below.

**Phosphoprotein enrichment.** Phosphoprotein enrichment was performed using phosphate metal affinity chromatography (TALON<sup>®</sup> PMAC Phosphoprotein Enrichment Kit, Clontech) columns, which allows for the selective binding of proteins that contain a phosphate group on any amino acid (including serine, threonine or tyrosine), according to the manufacturer’s instructions. Briefly, after the specified treatments, cells were washed with PBS, scrapped, centrifuged at 500 g for 5 min and the resulting pellet was frozen at –80 °C. Extraction/loading buffer was added to each sample according to pellet weight (30 µL buffer A/1mg of pellet), supplemented with sodium fluoride (a phosphatase inhibitor) to a final concentration of 10 mM. The samples were then incubated

at 4 °C for 10 min and centrifuged at 10,000 g, for 20 min at 4 °C. In parallel, columns were washed with distilled water and twice with extraction/loading buffer to equilibrate the columns.

The supernatants obtained by centrifugation (total phosphoproteins extracts) were added to the columns and shaken at 4 °C for 20 min, for phosphoprotein binding. After 4 washes, phosphorylated proteins were eluted using 1 ml of buffer B, for 4 times. From the 4 protein fractions obtained, fraction 2 contained the most enriched fraction, as determined by BCA assay (pierce). Samples were stored at –80 °C until lyophilization for MS analysis (Fig. 1).

**MS/MS Analysis and protein identification.** Lyophilized samples were dissolved in lithium dodecyl sulfate (LDS) buffer, incubated at 95 °C for 10 min, sonicated and loaded onto a one-dimensional polyacrylamide gel (1DE) system. Trypsin digestion of proteins to peptides occurred after 1DE staining with Coomassie blue and excision of the protein bands. Peptides were extracted from the gels using trifluoroacetic acid (TFA) 0.1% + ACN (50:50), and the resulting supernatant dried in SpeedVac, resuspended in TFA 0.1% and stored at –20 °C. Proteolytic samples were injected in the Q Exactive-Orbitrap LC-MS/MS System (Thermo Scientific) and MS/MS spectra data acquisition followed by phosphoprotein identification<sup>50–52</sup>, using proteome discovery software (Thermo Scientific). Semi-quantitative analysis of the data was carried out using the International Protein Index (IPI) database for protein search and *Rattus norvegicus* as the organism model. A false discovery rate of 1% was applied. A single phosphopeptide identification was set to be sufficient for phosphoprotein identification. Further data analysis was done similar to the black-and-white method used before<sup>50,52</sup>. Phosphoproteins resulting from each of the experiments were analyzed as described below.

**Bioinformatic and Statistical Analysis for phosphoprotein characterization using the SysBioTK library.** The Systems Biology Toolkit (SysBioTK) library was employed to analyze the data from each of the experimental conditions. For details see da Cruz e Silva, 2016 (submitted), available at <https://bitbucket.org/CrisXed/sysbiotk>. For the statistical analysis, each iteration of the experiment is considered a dataset. As a first step, the yield in terms of number of proteins for each dataset was used to identify the outlier datasets, using the modified Thompson tau,  $\tau$ , test with a confidence level of 95%. Subsequently, the protein IPI accession numbers were converted to the corresponding UniProt accession numbers. For this process, the cross references from the IPI database were used to identify the UniProt/Swiss-Prot accession numbers corresponding to each IPI accession number. For IPI accession numbers not identified, the SysBioTK BLAST+ parser was employed, with a similarity parameter of 0.90. The utility performs a blast search against a subset of the UniProt database (Swiss-Prot accession numbers, organism *rattus*), effectively identifying UniProt/SwissProt accession numbers corresponding to the IPI accession numbers. The process was then repeated, starting with the cross references, but against the UniProt/TrEMBL databases and only for the IPI accession numbers without a corresponding UniProt/SwissProt accession number. The analysis was carried out on the 27<sup>th</sup> of September 2015.

The datasets were grouped into two groups, one for each experimental condition (control and exposure to A $\beta$ ). The SysBioTK statistical analysis was employed to identify, between the two groups, which accession numbers were significantly different. For this purpose, the tool employed Welch's t-Test with a confidence level of 95%. Consequently, two protein lists were obtained; those where the retrieval of the phosphoprotein showed a significant decrease upon addition of A $\beta$  ('lower' phosphoproteins), and those where the retrieval of the phosphoprotein showed a significant increase upon addition of A $\beta$  ('higher' phosphoproteins). To produce the interacting networks, accession number lists were submitted to IntAct on the 29<sup>th</sup> of October 2015 and the information was loaded into Cytoscape 3.3.0<sup>53</sup>. Cluster analysis was carried out using the Cytoscape plugin clusterMaker (GJay). Significantly different phosphoproteins were also submitted to STRING, on the 3<sup>rd</sup> of December 2015, and resulting interactions were plotted using Cytoscape 3.3.0.

## References

- Vassar, R. BACE1: the beta-secretase enzyme in Alzheimer's disease. *J. Mol. Neurosci.* **23**, 105–114 (2004).
- Lee, S. F. *et al.* Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-?? precursor protein and Notch. *J. Biol. Chem.* **277**, 45013–45019 (2002).
- Citron, M. *et al.* Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. *Nature* **360**, 672–674 (1992).
- Zhang, H., Ma, Q., Zhang, Y. W. & Xu, H. Proteolytic processing of Alzheimer's beta-amyloid precursor protein. *J Neurochem* **120** Suppl, 9–21 (2012).
- Chow, V. W., Mattson, M. P., Wong, P. C. & Gleichmann, M. An overview of APP processing enzymes and products. *Neuromolecular Med* **12**, 1–12 (2010).
- Sisodia, S. S. Beta-amyloid precursor protein cleavage by a membrane-bound protease. *Proc Natl Acad Sci USA* **89**, 6075–6079 (1992).
- Tamaoka, A. *et al.* Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. *J Neurol Sci* **148**, 41–45 (1997).
- Haass, C. *et al.* Amyloid beta-peptide is produced by cultured cells during normal metabolism. *Nature* **359**, 322–325 (1992).
- Nabers, A. *et al.* Amyloid- $\beta$ -Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer's Disease. *Anal. Chem.* **88**, 2755–2762 (2016).
- Kamenetz, F. *et al.* APP processing and synaptic function. *Neuron* **37**, 925–937 (2003).
- Lesne, S. *et al.* NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. *J Neurosci* **25**, 9367–9377 (2005).
- Igbavboa, U., Sun, G. Y., Weisman, G. A., He, Y. & Wood, W. G. Amyloid beta-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes. *Neuroscience* **162**, 328–338 (2009).
- Lahiri, D. K. & Maloney, B. Beyond the signaling effect role of amyloid-ss42 on the processing of APP, and its clinical implications. *Exp Neurol* **225**, 51–54 (2010).
- Oliveira, J. M., Henriques, A. G., Martins, F. & Rebelo, S. & da Cruz e Silva, O. a B. Amyloid- $\beta$  Modulates Both A $\beta$ PP and Tau Phosphorylation. *J. Alzheimer's Dis.* **45**, 495–507 (2015).

15. da Cruz e Silva, E. F. & da Cruz e Silva, O. A. B. Protein phosphorylation and APP metabolism. *Neurochem. Res.* **28**, 1553–1561 (2003).
16. Di Domenico, F. *et al.* Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects. *J. Proteomics* **74**, 1091–1103 (2011).
17. Chung, S. H. Aberrant phosphorylation in the pathogenesis of Alzheimer's disease. *BMB Reports* **42**, 467–474 (2009).
18. Luo, Y., Sunderland, T. & Wolozin, B. Physiologic levels of beta-amyloid activate phosphatidylinositol 3-kinase with the involvement of tyrosine phosphorylation. *J. Neurochem* **67**, 978–987 (1996).
19. Sato, N. *et al.* Elevated amyloid beta protein(1-40) level induces CREB phosphorylation at serine-133 via p44/42 MAP kinase (Erk1/2)-dependent pathway in rat pheochromocytoma PC12 cells. *Biochem Biophys Res Commun* **232**, 637–642 (1997).
20. Williamson, R. *et al.* Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. *J. Neurosci* **22**, 10–20 (2002).
21. Huang, J. *et al.* Unilateral amyloid-beta25-35 injection into the rat amygdala increases the expressions of aberrant tau phosphorylation kinases. *Chin Med J* **123**, 1311–1314 (2010).
22. Otth, C. *et al.* AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. *J. Alzheimers. Dis.* **4**, 417–430 (2002).
23. McDonald, D. R., Bamberger, M. E., Combs, C. K. & Landreth, G. E. beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. *J. Neurosci* **18**, 4451–4460 (1998).
24. Vintém, A. P. B., Henriques, A. G., da Cruz e Silva, O. A. B. & da Cruz e Silva, E. F. PP1 inhibition by A $\beta$  peptide as a potential pathological mechanism in Alzheimer's disease. *Neurotoxicol. Teratol.* **31**, 85–88 (2009).
25. Henriques, A. G., Vieira, S. I., da Cruz, E. S. E. F. & da Cruz, E. S. O. A. Abeta promotes Alzheimer's disease-like cytoskeleton abnormalities with consequences to APP processing in neurons. *J. Neurochem* **113**, 761–771 (2010).
26. Braithwaite, S. P., Stock, J. B., Lombroso, P. & Nairn, A. *Protein Phosphatases and Alzheimer's Disease. Prog Mol Biol Transl Sci* **106** (2012).
27. Hunter, M. P. *et al.* Intersectin 1 contributes to phenotypes *in vivo*: implications for Down's syndrome. *Neuroreport* **22**, 767–772 (2011).
28. Pechstein, A. *et al.* Regulation of synaptic vesicle recycling by complex formation between intersectin 1 and the clathrin adaptor complex AP2. *Proc. Natl. Acad. Sci. USA* **107**, 4206–4211 (2010).
29. Reitz, C. Genetic loci associated with Alzheimer's disease. *Future Neurol.* **9**, 119–122 (2014).
30. Tian, Y., Chang, J. C., Fan, E. Y., Flajolet, M. & Greengard, P. Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy. *Proc. Natl. Acad. Sci. USA* **110**, 17071–17076 (2013).
31. Udayar, V. *et al.* A Paired RNAi and RabGAP overexpression screen identifies Rab11 as a regulator of  $\beta$ -amyloid production. *Cell Rep.* **5**, 1536–1551 (2013).
32. Scheper, W. *et al.* Rab6 is increased in Alzheimer's disease brain and correlates with endoplasmic reticulum stress. *Neuropathol. Appl. Neurobiol.* **33**, 523–532 (2007).
33. Butterfield, D. A., Hardas, S. S. & Lange, M. L. B. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and alzheimer's disease: Many pathways to neurodegeneration. *J. Alzheimer's Dis.* **20**, 369–393 (2010).
34. Manavalan, A. *et al.* Brain site-specific proteome changes in aging-related dementia. *Exp. Mol. Med.* **45**, e39 (2013).
35. Vieira, S. I., Rebelo, S., Domingues, S. C., Cruz e Silva, E. F. & Cruz e Silva, O. A. B. S655 phosphorylation enhances APP secretory traffic. *Mol. Cell. Biochem.* **328**, 145–154 (2009).
36. Vieira, S. I. *et al.* Retrieval of the Alzheimer's amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated. *Mol. Neurodegener.* **5** (2010).
37. Henriques, A. G., Vieira, S. I., Da Cruz E Silva, E. F. & Da Cruz E Silva, O. A. B. A $\beta$  hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures. *J. Mol. Neurosci.* **39**, 248–255 (2009).
38. Henriques, A. G. *et al.* Intracellular sAPP retention in response to A $\beta$  is mapped to cytoskeleton-associated structures. *J. Neurosci. Res.* **87**, 1449–1461 (2009).
39. Silver, M., Janousova, E., Hua, X., Thompson, P. M. & Montana, G. Identification of gene pathways implicated in Alzheimer's disease using longitudinal imaging phenotypes with sparse regression. *Neuroimage* **63**, 1681–1694 (2012).
40. Mendoza-Naranjo, A., Gonzalez-Billault, C. & Maccioni, R. B. Abeta1-42 stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases. *J. Cell Sci.* **120**, 279–288 (2007).
41. Nagashima, S., Kodaka, M., Iwasa, H. & Hata, Y. Magi2/S-Scam Outside Brain. *J. Biochem.* **157**, 177–184 (2015).
42. Proctor, D. T., Coulson, E. J. & Dodd, P. R. Reduction in post-synaptic scaffolding PSD-95 and SAP-102 protein levels in the Alzheimer inferior temporal cortex is correlated with disease pathology. *J. Alzheimers. Dis.* **21**, 795–811 (2010).
43. Martin, S. B. *et al.* Synaptophysin and synaptotagmin-1 in Down syndrome are differentially affected by Alzheimer's disease. *J. Alzheimers. Dis.* **42**, 767–775 (2014).
44. Shah, K., DeSilva, S. & Abbruscato, T. The role of glucose transporters in brain disease: Diabetes and Alzheimer's disease. *Int. J. Mol. Sci.* **13**, 12629–12655 (2012).
45. Kim, E. K. & Choi, E.-J. Pathological roles of MAPK signaling pathways in human diseases. *Biochim. Biophys. Acta* **1802**, 396–405 (2010).
46. Liang, D. *et al.* Concerted perturbation observed in a hub network in Alzheimer's disease. *PLoS One* **7**, e40498 (2012).
47. da Cruz e Silva, E. F. *et al.* Differential expression of protein phosphatase 1 isoforms in mammalian brain. *J. Neurosci.* **15**, 3375–3389 (1995).
48. Ouimet, C. C., da Cruz e Silva, E. F. & Greengard, P. The alpha and gamma 1 isoforms of protein phosphatase 1 are highly and specifically concentrated in dendritic spines. *Proc. Natl. Acad. Sci. USA* **92**, 3396–3400 (1995).
49. Henriques, A. G. *et al.* Complexing A $\beta$  prevents the cellular anomalies induced by the peptide alone. *J. Mol. Neurosci.* **53**, 661–668 (2014).
50. Schrötter, A. *et al.* FE65 Regulates and Interacts with the Bloom Syndrome Protein in Dynamic Nuclear Spheres - Potential Relevance to Alzheimer's Disease. *J. Cell Sci.* **126**, 2480–2492 (2013).
51. Schrotter, a. *et al.* The amyloid precursor protein (APP) family members are key players in S-adenosylmethionine formation by MAT2A and modify BACE1 and PSEN1 gene expression-relevance for Alzheimer's disease. *Mol Cell Proteomics* **11**, 1274–1288 (2012).
52. Nensa, F. M. *et al.* Amyloid beta a4 precursor protein-binding family B member 1 (FE65) interactomics revealed synaptic vesicle glycoprotein 2A (SV2A) and sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) as new binding proteins in the human brain. *Mol. Cell. Proteomics* **13**, 475–488 (2014).
53. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498–2504 (2003).

## Acknowledgements

This work was financed by iBiMED (UID/BIM/04501/2013) and also supported by JPND/0006/2011 – BIOMARKAPD; the Fundação para a Ciência e Tecnologia of the Ministério da Educação e Ciência; the COMPETE program, QREN and the European Union (Fundo Europeu de Desenvolvimento Regional) and

supported by PEst-OE/SAU/UI0482/2014 - Centro de Biologia Celular, Universidade de Aveiro. Both JO and CBCS are recipients of FCT fellowships (SFRH/BD/82486/2011 and SFRH/BD/76200/2011 respectively).

### Author Contributions

Authorship credit: O.B.C.S., A.G.H., T.M. and J.O. conceived, designed and performed the experiments, with input of M.C. and C.B.C.S. developed the SysBioTK and carried out the bioinformatics analysis.

### Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Henriques, A. G. *et al.* Altered protein phosphorylation as a resource for potential AD biomarkers. *Sci. Rep.* **6**, 30319; doi: 10.1038/srep30319 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016